Microbio Co Ltd (4128) - Total Liabilities
Based on the latest financial reports, Microbio Co Ltd (4128) has total liabilities worth NT$2.13 Billion TWD (≈ $67.09 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Microbio Co Ltd - Total Liabilities Trend (2006–2025)
This chart illustrates how Microbio Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See Microbio Co Ltd current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Microbio Co Ltd Competitors by Total Liabilities
The table below lists competitors of Microbio Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bera Holding AS
IS:BERA
|
Turkey | TL9.20 Billion |
|
Chien Kuo Construction Co Ltd
TW:5515
|
Taiwan | NT$5.77 Billion |
|
Te Chang Construction Co Ltd
TWO:5511
|
Taiwan | NT$7.01 Billion |
|
Ganesha Ecosphere Limited
NSE:GANECOS
|
India | Rs7.72 Billion |
|
PT Estee Gold Feet Tbk
JK:EURO
|
Indonesia | Rp6.06 Billion |
|
Bhansali Engineering Polymers Limited
NSE:BEPL
|
India | Rs2.02 Billion |
|
Akebia Ther
NASDAQ:AKBA
|
USA | $343.95 Million |
|
Highlight Tech
TWO:6208
|
Taiwan | NT$3.84 Billion |
Liability Composition Analysis (2006–2025)
This chart breaks down Microbio Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 4128 market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Microbio Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Microbio Co Ltd (2006–2025)
The table below shows the annual total liabilities of Microbio Co Ltd from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$2.13 Billion ≈ $67.09 Million |
+3.47% |
| 2024-12-31 | NT$2.06 Billion ≈ $64.84 Million |
+66.68% |
| 2023-12-31 | NT$1.23 Billion ≈ $38.90 Million |
+14.07% |
| 2022-12-31 | NT$1.08 Billion ≈ $34.10 Million |
-7.73% |
| 2021-12-31 | NT$1.17 Billion ≈ $36.96 Million |
+9.28% |
| 2020-12-31 | NT$1.07 Billion ≈ $33.82 Million |
+6.37% |
| 2019-12-31 | NT$1.01 Billion ≈ $31.79 Million |
+81.80% |
| 2018-12-31 | NT$555.11 Million ≈ $17.49 Million |
-35.41% |
| 2017-12-31 | NT$859.50 Million ≈ $27.08 Million |
+1.82% |
| 2016-12-31 | NT$844.17 Million ≈ $26.60 Million |
-5.09% |
| 2015-12-31 | NT$889.40 Million ≈ $28.02 Million |
+37.71% |
| 2014-12-31 | NT$645.86 Million ≈ $20.35 Million |
-22.56% |
| 2013-12-31 | NT$834.06 Million ≈ $26.28 Million |
-11.50% |
| 2012-12-31 | NT$942.47 Million ≈ $29.69 Million |
+128.87% |
| 2011-12-31 | NT$411.80 Million ≈ $12.97 Million |
-16.71% |
| 2010-12-31 | NT$494.42 Million ≈ $15.58 Million |
-22.59% |
| 2009-12-31 | NT$638.68 Million ≈ $20.12 Million |
+34.81% |
| 2008-12-31 | NT$473.77 Million ≈ $14.93 Million |
+6.83% |
| 2007-12-31 | NT$443.47 Million ≈ $13.97 Million |
+83.42% |
| 2006-12-31 | NT$241.78 Million ≈ $7.62 Million |
-- |
About Microbio Co Ltd
Microbio Co., Ltd. researches, develops, manufactures, and trades in biotech drugs and dietary supplements in Taiwan. The company provides MS-20 for fatigue and appetite loss associated with cancer chemotherapy; and Herbiron, which reveals symptoms of iron deficiency anemia in women before menopause and relieved dysmenorrhea. It also involved in the trading of organic foods; sale of beverages; pr… Read more